Reuters logo
BRIEF-Meridian Bioscience comments on FDA matter involving its subsidiary
May 17, 2017 / 7:56 PM / 6 months ago

BRIEF-Meridian Bioscience comments on FDA matter involving its subsidiary

May 17 (Reuters) - Meridian Bioscience Inc

* Meridian Bioscience comments on FDA matter involving its subsidiary, Magellan Diagnostics

* Unit currently working with U.S. Food and Drug Administration (FDA) regarding use of venous blood with its leadcare testing systems

* Meridian Bioscience Inc says unit’s capillary samples are not affected by notification

* FDA issued a warning that results from venous samples may be underestimated and provide inaccurate results

* Unit currently undertaking efforts to move customers to capillary blood testing with Leadcare II testing system as a corrective action

* Meridian and Magellan do not expect this occurrence to cause any material adverse effect to meridian’s financial results

* Meridian & Magellan will continue to work closely with FDA and CDC to address concerns identified with venous samples Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below